Share-Based Payments - Narrative (Details) $ / shares in Units, $ in Millions		1 Months Ended			3 Months Ended	12 Months Ended
	Sep. 26, 2023 USD ($)	Jun. 30, 2017 shares	Jun. 30, 2015 shares	May 31, 2006 shares	Mar. 31, 2019	Dec. 31, 2023 USD ($) increment plan $ / shares shares	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2021 USD ($) $ / shares	Dec. 31, 2014 increment
Share-based Compensation Arrangement by Share-based Payment Award
Selling, general and administrative						$ 2,549.7	$ 2,403.6	$ 2,674.3
Unrecognized compensation cost related to unvested share-based compensation						$ 287.4
Weighted-average period to recognize the cost of unvested awards (in years)						1 year 9 months 18 days
Number of share-based compensation plans pursuant to which awards are currently being made | plan						3
Granted (in shares) | shares						0
Shares issued under ESPP (in shares) | shares			6,200,000
Reata Pharmaceuticals, Inc
Share-based Compensation Arrangement by Share-based Payment Award
Operating expenses	$ 393.4
Selling, general and administrative	196.4
Research and development expense asset acquired	$ 197.0
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award
Share based payment arrangement, term						10 years
Market Stock Units (MSUs)
Share-based Compensation Arrangement by Share-based Payment Award
Number of equal annual increments | increment						3			4
Percentage of earnings of the target number of units granted based on actual stock performance						0.00%			0.00%
Percentage of earnings of the target number of units granted based on actual stock performance						200.00%			150.00%
Weighted average grant date fair value, nonvested | $ / shares						$ 359.77	$ 366.52	$ 358.77
Total fair value of vested awards						$ 20.7	$ 18.8	$ 22.5
Granted (in dollars per share) | $ / shares						$ 0		$ 358.77
Performance Units (PUs)
Share-based Compensation Arrangement by Share-based Payment Award
Number of days for calculation of average closing stock price						30 days
Total fair value of vested awards						$ 28.6	$ 9.5	$ 15.5
PSUs Settled in Stock
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period					3 years
Percentage of earnings of the target number of units granted based on actual stock performance						0.00%
Percentage of earnings of the target number of units granted based on actual stock performance						200.00%
Weighted average grant date fair value, nonvested | $ / shares						$ 325.73	$ 292.95
Granted (in dollars per share) | $ / shares						$ 383.61	$ 294.43	$ 276.61
PSUs Settled in Cash
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period					3 years
Percentage of earnings of the target number of units granted based on actual stock performance						0.00%
Percentage of earnings of the target number of units granted based on actual stock performance						200.00%
Number of days for calculation of average closing stock price						30 days
Total fair value of vested awards						$ 11.7	$ 11.0	$ 9.9
Granted (in dollars per share) | $ / shares						$ 383.61	$ 294.43
Time-Vested Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period						3 years
Weighted average grant date fair value, nonvested | $ / shares						$ 256.74	$ 237.90
Total fair value of vested awards						$ 232.1	$ 116.3	$ 132.2
Granted (in dollars per share) | $ / shares						$ 282.92	$ 221.28	$ 276.90
Directors Plan
Share-based Compensation Arrangement by Share-based Payment Award
Total number of shares of common stock for issuance (in shares) | shares				1,600,000
Ratio of total number of shares reserved under the plan				1.5
2017 Omnibus Equity Plan
Share-based Compensation Arrangement by Share-based Payment Award
Ratio of total number of shares reserved under the plan		1.5
Omnibus Plan number of shares authorized (in shares) | shares		8,000,000
2017 Omnibus Equity Plan | Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award
Granted (in shares) | shares						81,000
Stock options granted, weighted average price (in dollars per share) | $ / shares						$ 139.10
Stock options granted, grant date fair value						$ 11.2
Vesting period						3 years